L-Alanine.

Muscle exports nitrogen as both alanine and glutamine, and the liver takes alanine back to make glucose while glutamine feeds the gut and kidney. Supplying both covers the two main nitrogen shuttles that run in parallel.

Alanine aminotransferase moves the amino group between alanine and pyruvate using pyridoxal-5-phosphate as its cofactor. Without adequate active B6 the alanine to pyruvate step slows.

Pyridoxine is converted to pyridoxal-5-phosphate, the cofactor every alanine transamination step depends on. Alanine metabolism is one of the classic markers of B6 status for this reason.

Branched-chain amino acids donate their amino groups to pyruvate in muscle, and alanine is the product carried out to the liver. Leucine intake therefore raises alanine output through a direct transamination link.

Isoleucine transamination in muscle hands its amino group to pyruvate, forming alanine. The two amino acids are linked by a single enzymatic step rather than by a general pathway.

Valine is transaminated in muscle with pyruvate as the acceptor, producing alanine that carries the nitrogen to the liver. Valine load and alanine output move together.

Alanyl-glutamine is the alanine and glutamine pair joined as one dipeptide with better solution stability than free glutamine. A formula holding both supplies the same alanine residue in free and bound form.

Glycine and alanine are both small neutral amino acids moving through the same system A and ASC carriers, so they share transport capacity. They also appear together in the repeating collagen sequence.

Alanine converts to pyruvate, and pyruvate carboxylase requires biotin to carry it into gluconeogenesis. Biotin status therefore gates what the liver does with the alanine that arrives.

Neutral amino acids including alanine cross the intestinal brush border on B0AT1 (SLC6A19), a sodium-dependent cotransporter, so the sodium gradient set up by the basolateral Na/K-ATPase is what drives alanine uptake. This is the same coupling that oral rehydration formulas exploit with glucose. It is a requirement of the transport step, not a reason to add sodium.

Alanine, serine, cysteine and threonine are the defining substrates of the ASC transport system, and they share B0AT1 at the brush border as well. Given together in free form at high concentration they compete for the same carriers, which flattens individual peak plasma appearance. The competition is a kinetic effect on timing rather than a loss of the amino acid.

Cysteine is carried by the same ASC-system transporters as alanine and by B0AT1, so co-ingestion of free forms produces mutual competition at the absorptive surface. Protein-bound amino acids arrive as di- and tripeptides on PepT1 instead and largely sidestep this. That is why competition matters for free-form powders and much less for whole protein.

B0AT1 accepts both small and large neutral amino acids, so free alanine and free tryptophan compete for intestinal entry, and the large neutral amino acids compete again at LAT1 on the blood-brain barrier. A large free-alanine dose alongside tryptophan changes the relative rate at which each appears in plasma. Whether that shifts any downstream measure has not been established here.

Methionine is a neutral amino acid handled by B0AT1, the same carrier alanine uses. Free forms taken together at gram doses compete for that carrier. Separating the doses removes the competition; taking them inside a protein largely avoids it.

Histidine is transported as a neutral amino acid at the brush border and shares carrier capacity with alanine. The interaction shows up as altered appearance kinetics rather than reduced total absorption over a meal. Marked as a timing effect, not a deficiency risk.

Alanine is transaminated to pyruvate, and the main oxidative fate of pyruvate is decarboxylation by the pyruvate dehydrogenase complex, whose E1 subunit requires thiamine pyrophosphate. Without adequate thiamine, pyruvate accumulates and is shunted to lactate instead. This is textbook cofactor dependence downstream of alanine, not an effect of taking the two together.

The E3 subunit of the pyruvate dehydrogenase complex, dihydrolipoamide dehydrogenase, uses FAD, which is made from riboflavin. Alanine-derived pyruvate cannot be oxidised through that complex without it. Established cofactor requirement rather than a measured pairing.

Lipoic acid is the swinging arm on the E2 subunit that carries the acetyl group during pyruvate decarboxylation, the step alanine feeds through pyruvate. Important caveat: the enzyme cofactor is lipoate covalently attached by lipoyltransferase, and supplemental free alpha-lipoic acid is not incorporated into the complex. The pathway relevance is real; the supplement does not fill that particular slot.

Pyruvate carboxylase and phosphoenolpyruvate carboxykinase, the first two committed steps of making glucose from alanine-derived pyruvate, both use nucleotide substrates as their magnesium chelates. Magnesium is not optional for those reactions. This is standard enzymology behind the pathway alanine enters.

Alanine is one of the two main carriers moving amino nitrogen from muscle to the liver, and once the amino group is released it must be committed to urea. Ornithine is the carrier molecule regenerated on every turn of that cycle. Handling more alanine nitrogen means running that cycle more, which is where ornithine sits.

Arginine is the immediate precursor of urea in the cycle and is cleaved by arginase to release urea and regenerate ornithine. It is also the allosteric activator of N-acetylglutamate synthase, which switches on the first step of the cycle. Both facts place it downstream of the nitrogen alanine delivers to the liver.

Whey already supplies alanine as part of its amino acid profile, delivered as peptides absorbed on PepT1 rather than as competing free amino acids. Adding free alanine on top of a whole protein changes absorption kinetics more than it changes total intake. Trade-off: the free form arrives faster and competes at the transporter, the bound form arrives more evenly.

Alanine aminotransferase moves the amino group of L-alanine onto alpha-ketoglutarate, producing pyruvate and glutamate. Without an alpha-keto acid acceptor the transamination cannot proceed in that direction. The pairing is textbook enzymology rather than a tested supplement combination.

Glutamate is the direct product when alanine gives up its nitrogen in the ALT reaction, and the reaction is freely reversible. Glutamate availability therefore sets which way the equilibrium sits. This is amino group traffic between two interconvertible pools, not a claimed additive effect.

Enzymatic decarboxylation of L-aspartate by aspartate beta-decarboxylase yields L-alanine, which is one of the routes used to manufacture it. Metabolically both amino acids feed nitrogen into transamination and the urea cycle. The relationship is precursor to product on the same carbon and nitrogen accounting.

Pyruvate is the carbon skeleton of L-alanine; a single transamination step separates them. When nitrogen needs exporting from muscle, pyruvate accepts it and leaves as alanine. Pyruvate availability is what caps that shuttle.

Niacin supplies NAD, and the gluconeogenic steps that consume alanine-derived pyruvate in the liver are NAD dependent. Lactate dehydrogenase and glyceraldehyde-3-phosphate dehydrogenase both draw on that pool. Cofactor supply is the whole basis; no combination trial is involved.

Thiamine pyrophosphate is the cofactor of pyruvate dehydrogenase, which sends pyruvate into acetyl-CoA and the TCA cycle. That is a competing fate for the same pyruvate that alanine transamination generates. Thiamine status therefore shifts where alanine-derived carbon goes rather than adding to an effect.

Threonine is another small neutral amino acid handled by the same sodium-coupled neutral transporters that carry alanine. A large single bolus of one can slow the uptake rate of the other across that carrier. Spacing doses is the practical consequence.

The taurine transporter TauT prefers beta-amino acids, and alanine has been described as a competing substrate or inhibitor at that carrier in some tissues. The degree of interference depends on the tissue and the concentrations involved. This is transporter pharmacology in cells, not a human co-dosing study.

Casein is another intact dairy protein carrying alanine in its sequence, released slowly during digestion. Adding free alanine changes the timing profile of appearance, not the identity of what appears. The two overlap on total alanine intake.

Beta-alanine is a beta-amino acid with the amino group on the third carbon and it is the rate-limiting precursor to carnosine when combined with histidine. L-alanine is an alpha-amino acid used in protein synthesis and in the glucose-alanine cycle, and it does not serve as that carnosine precursor. Much of the sports literature filed under alanine is in fact beta-alanine work, and the two are not interchangeable.

L-alanine is a gluconeogenic substrate and a stimulus for glucagon release, so it sits on the glucose-raising side of the ledger. Chromium is studied for insulin signalling and glucose handling in the other direction. Anyone tracking blood sugar closely should know both inputs are present; there is no trial of the pair.

Berberine is studied for AMPK-related effects on glucose handling, including suppression of hepatic glucose output. Alanine is a substrate for exactly that hepatic gluconeogenic output. The directions oppose each other mechanistically, which is a reason to note the pairing rather than assume it cancels.

Creatine buffers short-term ATP demand through creatine kinase, while alanine contributes to the slower glucose-alanine nitrogen and carbon shuttle between muscle and liver. They sit on different timescales of the same energy economy. Preclinical amino acid work has looked at alanine alongside branched-chain amino acids for exercise measures, but not with creatine.